BIOFRONTERA INC -CW26 (BFRIW) Stock News

NASDAQ:BFRIW - Nasdaq - - Currency: USD

0.15 -0.03 (-16.67%)

Technical Analysis

BFRIW Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Biofrontera Inc. - Mentions: BFRI

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

2 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

3 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

3 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

3 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

5 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

5 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

5 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

7 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

7 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

8 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

9 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

9 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

10 months ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

10 months ago - By: Biofrontera Inc. - Mentions: BFRI

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

a year ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

a year ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

3 years ago - By: Biofrontera Inc. - Mentions: BFRI

Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan